Skip to main content

Table 1 Studies on mutation status of KRAS , BRAF and PIK3CA in Chinese CRC patients

From: BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients

Reference (year) No. of patients Method Mutation frequencies Region Prognostic value
[2] Gao J., et al. (2011) 273 Direct sequencing KRAS (38.5%); BRAF (5.1%) Chinese  
[24] Li H.T., et al. (2011) 200 Pyrosequencing KRAS (31.5%); BRAF (7.0%); PIK3CA (12.5%) Chinese KRAS and PIK3CA bi-mutations were more likely to develop liver metastases.
[25] Shen H., et al. (2011) 118 Pyrosequencing KRAS (34.7%); BRAF (1.7%) Chinese  
[26] Liou J.M., et al. (2011) 314 Direct sequencing KRAS (20.7%); BRAF (3.8%) Taiwan BRAF mutation was associated with worse overall survival.
[27] Mao C., et al. (2012) 69 Direct sequencing KRAS (43.9%); BRAF (25.4%); PIK3CA (8.2%) Chinese  
[28] Hsieh L.L., et al. (2012) 182 Direct sequencing & HRM KRAS (33.5%); BRAF (1.1%); PIK3CA (7.1%) Taiwan  
[29] Zhu Y.F., et al. (2012) 60 Direct sequencing PIK3CA (21.6%) Chinese High PI3K expression was associated with CRC metastases.
[30] Li Z., et al. (2012) 78 Direct sequencing KRAS (33.3%) Chinese KRAS mutations were associated with poor survival and liver metastasis.
[31] Shen Y., et al. (2013) 676 Direct sequencing KRAS (35.9%); BRAF (6.96%); PIK3CA (9.9%) Chinese  
[32] Pu X., et al. (2013) 115 Direct sequencing KRAS (32.2%); BRAF (3.5%) Chinese  
[33] Wang J., et al. (2013) 574 Direct sequencing KRAS (34.2%) Chinese  
[34] Chang Y.S., et al. (2013) 165 HRM KRAS (36.97%); BRAF (4.24%) Taiwan KRAS mutation was associated with poor survival.